Corporate GovernanceApr 29, 2026, 04:36 PM
ELTX Amends 10-K to Include Part III Info; Updates Market Value
AI Summary
Elicio Therapeutics, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. The amendment includes information required by Part III, which covers directors, executive officers, and corporate governance, and updates the exhibit list in Part IV with new certifications. The filing also disclosed an aggregate market value of voting stock held by non-affiliates of approximately $81.8 million as of June 30, 2025, and 18,704,798 shares outstanding as of April 9, 2026.
Key Highlights
- ELTX's aggregate market value of voting stock held by non-affiliates was approximately $81.8 million as of June 30, 2025.
- 18,704,798 shares of common stock were outstanding as of April 9, 2026.
- The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
- The Board of Directors consists of 8 members, with 5 determined to be independent.
- Executive officers include Robert Connelly (CEO), Preetam Shah (CSFO), Christopher Haqq (EVP, R&D, CMO), and Peter DeMuth (CSO).
Price Impact
More from ELTX